IMCR — Immunocore Holdings Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapHigh Flyer

Annual cashflow statement for Immunocore Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	C2020 December 31st	R2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	20-F	10-K	10-K	10-K	10-K
Standards:	IFRS	USG	USG	USG	USG
Status:	fx Final	Final	Final	Final	Final
Net Income/Starting Line	-95	-180	-52.5	-55.3	-51.1
Depreciation
Amortisation
Non-Cash Items	-9.73	51.3	22.2	48.4	27.8
Unusual Items
Other Non-Cash Items
Changes in Working Capital	14.7	-22	-24.2	5.78	45.1
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-78.5	-143	-49.2	2.94	26.1
Capital Expenditures	-3.94	-1.39	-2.2	-5.42	-5.17
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	5.41	0.106	0.006	0	-350
Sale of Fixed Assets
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	1.47	-1.28	-2.2	-5.42	-355
Financing Cash Flow Items	-0.226	—	-1.77	0	-13.4
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	149	288	145	34.3	344
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	71.5	144	81.4	40.2	13.1